BVMS: Biblioteca Virtual Murciasalud,
Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on…
Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on…
#PubSaludMurcia Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in pre... http://ow.ly…